Mediomics, LLC has exclusively licensed worldwide commercial development rights of proprietary technologies developed in the laboratories of Professor Yie-Hwa Chang, Ph.D. and Professor Tomasz Heyduk, Ph.D. at the Saint Louis University School of Medicine, as well as technology developed in the laboratory of Professor David M. Waisman, Ph.D., at the University of Calgary School of Medicine, in Alberta, Canada. Two of these technologies, one developed in Dr. Changâs laboratory and the other developed in the laboratory of Dr. Waisman, relate to different anti-angiogenesis therapeutic compositions. The technology developed in the laboratory of Dr. Heyduk relates to a novel assay platform that will be used in the development of in vitro assays for easily and reliably measuring the activity of DNA-binding proteins and their co-regulators (ligands
